OctaPharma

Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective, specific, cost effective, and less toxic than existing available treatments.

Apr 13, 2018

Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper